The prognosis of unresectable GC is very poor, even targeted therapy for human epidermal growth factor receptor-2 (HER-2) makes an improved overall survival (OS) of less than 16 months (Bang et al., 2010; Shen et al., 2013). This evidence concerns the gene ERBB2 and gastric cancer.